Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma - Authors' reply
- PMID: 34339649
- DOI: 10.1016/S1470-2045(21)00418-6
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma - Authors' reply
Conflict of interest statement
MJvdB reports grants from the Dutch Cancer Foundation, Brain Tumor Charity, Strijd van Salland, and Merck Sharp & Dohme (formerly Schering Plough), during the conduct of the study; and personal fees from Carthera, Nerviano, Bayer, Cellgene, Agios, AbbVie, Karyopharm, Boston Pharmaceuticals, and Genenta, outside the submitted work. MT declares no competing interests.
Comment on
-
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.Lancet Oncol. 2021 Jun;22(6):813-823. doi: 10.1016/S1470-2045(21)00090-5. Epub 2021 May 14. Lancet Oncol. 2021. PMID: 34000245 Free PMC article. Clinical Trial.
-
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma.Lancet Oncol. 2021 Aug;22(8):e345. doi: 10.1016/S1470-2045(21)00378-8. Lancet Oncol. 2021. PMID: 34339648 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources